Biologics for Targeting Inflammatory Cytokines, Clinical Uses, and Limitations

Beck, P. L., & Wallace, J. L. (1997). Cytokines in inflammatory bowel disease. Mediators of Inflammation, 1997(), 95-103. https://doi.org/10.1080/09629359791785
Fei, P. C., Bianchi, L., Bonifati, C., Trento, E., Ruzzetti, M., Francesconi, F., Bultrini, S., D’Agosto, G., Bordignon, V., Francavilla, V., Tripiciano, A., Chiricozzi, A., Campione, E., Cavallotti, C., Orlandi, A., Berardesca, E., Carlo, A. D., Chimenti, S., & Ensoli, F. (2014). Immunologic Biomarkers for Clinical and Therapeutic Management of Psoriasis. Mediators of Inflammation, (2014-2), 129-139. https://doi.org/10.1155/2014/236060
郭曉萱、陳偉武（2018）。Managing the Adverse Effects Related to Immune Checkpoint Inhibitors。護理雜誌，65(3)，88-95。https://doi.org/10.6224/JN.201806_65(3).12
魏淑鉁（2018）。Immunomodulators and Biologics for Inflammatory Bowel Diseases。台灣醫學，22(4)，405-410。https://doi.org/10.6320/FJM.201807_22(4).0007
Smith, G. R., & Jewell, D. P. (1994). The role of cytokines in inflammatory bowel disease. Mediators of Inflammation, 1994(), 3-9. https://doi.org/10.1155/S0962935194000013